** Australian biopharma firm Telix Pharmaceuticals TLX.AX
rises as much as 10.4% to A$7.25, biggest intraday pct jump
since June 25
** Says https://telixpharma.com/investors/# U.S. Food and
Drug Administration accepted its Investigational New Drug
Application to conduct clinical study of TLX's investigational
kidney cancer therapy, TLX250
** Expects to enrol 29 patients in phase-2 study to
determine efficacy of the therapy to treat kidney tumours
** TLX hits highest since Sept 3; set for a second straight
gain session
** Stock fourth-biggest percentage gainer in the ASX All
Ordinaries index .AORD
** TLX up 73.8% this year, as of last close, vs a 12.8%
increase in the ASX All Ordinaries index .AORD
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com;))